Additionally, in direct prospective comparison with fluciclovine, PSMA was associated with better detection rates of prostate cancer overall, although fluciclovine outperformed it in the prostate bed where urinary accumulation of the PSMA-tracer can conceal local recurrence [56,78]. This evidence concerns the gene FOLH1 and Familial prostate cancer.